Why the study?
Patient management is guided by CMR diagnosis in suspected cardiac tumours, but outcomes studies validating this approach were lacking.
Does cardiovascular magnetic resonance imaging predict all-cause mortality in patients with suspected cardiac tumours?
Does cardiovascular magnetic resonance imaging predict all-cause mortality in patients with suspected cardiac tumours?
CMR provides high diagnostic accuracy and independent prognostic value for long-term mortality in patients with suspected cardiac tumours.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These data provide the first large-scale validation of the clinical practice of using CMR to exclude a cardiac tumor and to diagnose the type of tumor. By demonstrating high accuracy and long-term prognostic value, our results confirm that CMR can be used as a 'one-stop-shop' for this clinical indication. We anticipate our findings will shape future guidelines, appropriateness documents and health policies on this topic.”
“Our findings show that CMR should be the imaging modality of choice for the assessment of patients with suspected cardiac tumors, and physicians can use it as the only imaging test for virtually all patients—a 'one-stop shop'—that provides accurate data on diagnosis and prognosis.”
“The big-picture message that this paper highlights in a systematic fashion is that MRI is highly diagnostically powerful as well as prognostically useful.”
Supports CMR-based prognostic stratification of cardiac masses; leaves open impact of imaging-guided therapy on outcomes.
AIMS: Cardiovascular magnetic resonance (CMR) imaging is a key diagnostic tool for the evaluation of patients with suspected cardiac tumours. Patient management is guided by the CMR diagnosis, including no further testing if a mass is excluded or if only a pseudomass is found. However, there are no outcomes studies validating this approach. METHODS AND RESULTS: In this multicentre study of patients undergoing clinical CMR for suspected cardiac tumour, CMR diagnoses were assigned as no mass, pseudomass, thrombus, benign tumour, or malignant tumour. A final diagnosis was determined after follow-up using all available data. The primary endpoint was all-cause mortality. Among 903 patients, the CMR diagnosis was no mass in 25%, pseudomass in 16%, thrombus in 16%, benign tumour in 17%, and malignant tumour in 23%. Over a median of 4.9 years, 376 patients died. Compared with the final diagnosis, the CMR diagnosis was accurate in 98.4% of patients. Patients with CMR diagnoses of pseudomass and benign tumour had similar mortality to those with no mass, whereas those with malignant tumour [hazard ratio (HR) 3.31 (2.40-4.57)] and thrombus [HR 1.46 (1.00-2.11)] had greater mortality. The CMR diagnosis provided incremental prognostic value over clinical factors including left ventricular ejection fraction, coronary artery disease, and history of extracardiac malignancy (P < 0.001). CONCLUSION: In patients with suspected cardiac tumour, CMR has high diagnostic accuracy. Patients with CMR diagnoses of no mass, pseudomass, and benign tumour have similar long-term mortality. The CMR diagnosis is a powerful independent predictor of mortality incremental to clinical risk factors.
No takes yet. Share an insight, caveat, or question.
Shenoy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: